瑞替普酶溶栓联合疏血通治疗急性ST段抬高型心肌梗死的临床观察

目的 应用瑞替普酶溶栓联合疏血通注射液治疗急性ST段抬高型心肌梗死（ST-segment elevation myocardial infarction,STEMI）患者,评价其再通率、疗效和安全性.方法 将89例经瑞替普酶溶栓的STEMI患者随机分为两组,治疗组联合疏血通治疗,对照组单纯溶栓治疗.比较两组患者溶栓后的再通率、疗效情况,和出血不良反应的发生率.结果 治疗组和对照组总再通率比较无显著改变（P＞0.05）,但治疗组胸闷、胸痛等自觉症状改善明显,硝酸酯类药物用量有不同程度减少,心电图示前抬高的ST段下降幅度较大；治疗组总有效率较对照组显著升高（P＜0.05）；两组患者出血的发生率比较无显著改变（P＞0.05）.结论 瑞替普酶溶栓联合疏血通治疗STEMI患者疗效确切,安全可靠.

Clinical observation on patients of acute ST-segment elevation myocardial infarction treated with Shuxuetong injection after thrombolysis with Reteplase

Objective To evaluate the therapeutic effects and safety of treating ST-segment elevation myocardial infarction （STEMI） with Shuxuetong injection after thrombolysis with Reteplase. Methods Eighty-nine patients with STEMI were randomly divided into two groups., the research group was treated with Shuxuetong injection after thrombolysis with Reteplase while the control group was treated only with Reteplase. The regression of clinical symptoms, the response of reperfusion, as well as the incidence of bleeding complications in the two groups were observed and compared. Results Although the reperfusion rate in the research group was not significantly different from the control group （P〉0.05）, the efficacy was more robust than it in the control group （P〈0.05）, as the percentage of symptom remission was more pronounced, the dose of nitrates needed was lesser and the depression of previously elevated ST-segment was grater. Meanwhile, the rate of bleeding complications in the two groups was similar （P〉0.05）. Conclusion Treatment with Reteplase and Shuxuetong is effective and safe for patients with STEMI.